Business news for the stock market
Leverkusen, Germany (pta032/28.04.2022/11:35) - Biofrontera AG (ISIN: DE0006046113, US OTC: BFAGY), an international biopharmaceutical company, announces that the publication of the Annual Report will be postponed to Friday, April 29, 2022.
The conference call, in which the Management Board will provide information on key developments in the reporting period, will be rescheduled to Monday, May 2, 2022.
The corresponding dates and dial-in details are listed below.
The conference call for shareholders and interested investors will start at 11:30 a.m. in German and at 2:00 p.m. in English.
Conference Call - GERMAN
May 02, 2022, 11:30 a.m. CEST (5:30 a.m. ET)
Dial-in number: +49 69201744220
Confirmation number: 47974148 #
Conference Call - ENGLISH
May 02, 2022, 2:00 p.m. CEST (8:00 a.m. ET)
Dial-in number USA: +1 8774230830
Dial-in number UK: +44 2030092470
Confirmation number: 59031521 #
Please dial in as early as 10 minutes prior to the start of the conference call to ensure an on-time start.
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Leverkusen-based company develops and markets innovative products for the treatment, protection and care of the skin. Its key products include Ameluz®, a prescription drug for the treatment of non-melanoma skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the USA since May 2016. In Europe, the company also markets the Belixos® dermocosmetic series, a specialty care product for damaged skin. Biofrontera is one of a few German pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on US OTC market (BFAGY). www.biofrontera.com
emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate
other stock exchanges: US OTC